Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 April 2007, Vol. 109, No. 7, pp. 2989-2998.
Prepublished online as a Blood First Edition Paper on December 5, 2006; DOI 10.1182/blood-2006-10-051110.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Methods, Tables, and Figures
Right arrow All Versions of this Article:
blood-2006-10-051110v1
109/7/2989    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bomben, R.
Right arrow Articles by Gattei, V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bomben, R.
Right arrow Articles by Gattei, V.
Related Collections
Right arrow Neoplasia
Right arrow Clinical Trials and Observations
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

NEOPLASIA

Comprehensive characterization of IGHV3-21–expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study

Riccardo Bomben1, Michele Dal Bo1, Daniela Capello2, Dania Benedetti1, Daniela Marconi3, Antonella Zucchetto1, Francesco Forconi4, Rossana Maffei5, Emanuela M. Ghia6, Luca Laurenti7, Pietro Bulian1, Maria Ilaria Del Principe8, Giuseppe Palermo3, Mia Thorsélius9, Massimo Degan1, Renato Campanini3, Anna Guarini5, Giovanni Del Poeta8, Richard Rosenquist9, Dimitar G. Efremov10, Roberto Marasca5, Robin Foà6, Gianluca Gaidano2, and Valter Gattei1

1 Clinical and Experimental Hematology Research Unit, Centro di Riferimento Oncologico, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Aviano (PN, Italy); 2 Division of Hematology, Department of Clinical and Experimental Medicine and Interdisciplinary Research Center on Autoimmune Diseases (IRCAD), Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; 3 Department of Physics, University of Bologna, Italy; 4 Division of Hematology and Transplant, Department of Clinical Medicine and Immunological Sciences, University of Siena, Italy; 5 Division of Hematology, Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena, Italy; 6 Division of Hematology, Department of Cellular Biotechnologies and Hematology, University La Sapienza, Rome, Italy; 7 Hematology Institute, Catholic University Sacro Cuore, Rome, Italy; 8 Chair of Hematology, S Eugenio Hospital and University of Tor Vergata, Rome, Italy; 9 Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Sweden; 10 International Centre for Genetic Engineering and Biotechnology (ICGEB) Outstation-Monterotondo, Consiglio Nazionale delle Ricerche (CNR) Campus A. Buzzati-Traverso, Rome, Italy

IGHV3-21–using chronic lymphocytic leukemia (CLL) is a distinct entity with restricted immunoglobulin gene features and poor prognosis and is more frequently encountered in Northern than Southern Europe. To further investigate this subset and its geographic distribution in the context of a country (Italy) with both continental and Mediterranean areas, 37 IGHV3-21 CLLs were collected out of 1076 cases enrolled by different institutions from Northern or Central Southern Italy. Of the 37 cases, 18 were identified as homologous (hom)HCDR3–IGHV3-21 CLLs and were found almost exclusively (16 of 18) in Northern Italy; in contrast, 19 nonhomHCDR3–IGHV3-21 cases were evenly distributed throughout Italy. Clinically, poor survivals were documented for IGHV3-21 CLLs as well as for subgroups of mutated and homHCDR3–IGHV3-21 CLLs. Negative prognosticators CD38, ZAP-70, CD49d, and CD79b were expressed at higher levels in homHCDR3 than nonhomHCDR3–IGHV3-21 cases. Differential gene expression profiling (GEP) of 13 IGHV3-21 versus 52 non–IGHV3-21 CLLs identified, among 122 best-correlated genes, TGFB2 and VIPR1 as down- and up-regulated in IGHV3-21 CLL cases, respectively. Moreover, GEP of 7 homHCDR3 versus 6 nonhomHCDR3–IGHV3-21 CLLs yielded 20 differentially expressed genes, with WNT-16 being that expressed at the highest levels in homHCDR3–IGHV3-21 CLLs. Altogether, IGHV3-21 CLLs, including those with homHCDR3, had a peculiar global phenotype in part explaining their worse clinical outcome.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
E. M. Ghia, S. Jain, G. F. Widhopf II, L. Z. Rassenti, M. J. Keating, W. G. Wierda, J. G. Gribben, J. R. Brown, K. R. Rai, J. C. Byrd, et al.
Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection
Blood, May 15, 2008; 111(10): 5101 - 5108.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
F. Forconi, E. Sozzi, D. Rossi, S. S. Sahota, T. Amato, D. Raspadori, L. Trentin, L. Leoncini, G. Gaidano, and F. Lauria
Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia
Haematologica, May 1, 2008; 93(5): 697 - 705.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
V. Gattei, P. Bulian, M. I. Del Principe, A. Zucchetto, L. Maurillo, F. Buccisano, R. Bomben, M. Dal-Bo, F. Luciano, F. M. Rossi, et al.
Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia
Blood, January 15, 2008; 111(2): 865 - 873.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020